ストックスクリーナーアプリを入手
24.35
2.48%
0.5884
Arrivent Biopharma Inc (AVBP) 最新ニュース
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $36.00 by Analysts at Citigroup - Defense World
Citigroup Raises ArriVent BioPharma (NASDAQ:AVBP) Price Target to $36.00 - MarketBeat
ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer - Scrip
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.3% - MarketBeat
Global economic uncertainty takes toll on China’s biotech ecosystem - BioWorld Online
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $36.00 at HC Wainwright - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst Upgrade - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $38.00 by Analysts at The Goldman Sachs Group - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up Following Analyst Upgrade - Defense World
ArriVent BioPharma shares see boost as Citi ups price target By Investing.com - Investing.com Canada
ArriVent BioPharma stock target raised on positive trial results By Investing.com - Investing.com Canada
ArriVent BioPharma shares see boost as Citi ups price target By Investing.com - Investing.com UK
ArriVent BioPharma's (AVBP) Outperform Rating Reaffirmed at Oppenheimer - MarketBeat
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
ArriVent BioPharma (NASDAQ:AVBP) Price Target Increased to $38.00 by Analysts at The Goldman Sachs Group - MarketBeat
Should investors be concerned about ArriVent BioPharma Inc. (AVBP)? - US Post News
Analyst boosts ArriVent BioPharma shares price target after promising trial data - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume Increase - MarketBeat
ArriVent reports promising data on lung cancer drug firmonertinib - Investing.com
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - ForexTV.com
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib - The Bakersfield Californian
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - StockTitan
ArriVent BioPharma (NASDAQ:AVBP) Trading 3.2% Higher - MarketBeat
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Yahoo Finance
ArriVent, lung cancer drug developer, files for $100M IPO - MSN
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 2.4% - MarketBeat
ArriVent BioPharma Inc. Inc. (AVBP) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
ArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week High at $26.24 - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Sets New 12-Month High at $26.24 - MarketBeat
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress - MSN
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung - Quantisnow
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet - Yahoo Finance
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength - Yahoo Canada Finance
Oppenheimer Reiterates Outperform Rating for ArriVent BioPharma (NASDAQ:AVBP) - Defense World
H.C. Wainwright ups ArriVent BioPharma shares target on clinical trial catalysts - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $30.00 at HC Wainwright - MarketBeat
HC Wainwright Boosts ArriVent BioPharma (NASDAQ:AVBP) Price Target to $30.00 - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Issues Quarterly Earnings Results - Defense World
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Announces Earnings Results - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Given Outperform Rating at Oppenheimer - MarketBeat
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Business Wire
ArriVent BioPharma Reports Second Quarter 2024 Financial Results - wallstreet:online
648,735 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Vanguard Group Inc. - Defense World
648,735 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Bought by Vanguard Group Inc. - MarketBeat
ArriVent BioPharma Reports Second Quarter 2024 Financial Results - StockTitan
ArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung Cancer - MyChesCo
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer - StockTitan
(AVBP) Proactive Strategies - Stock Traders Daily
4,845 Shares in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Acquired by American International Group Inc. - Defense World
Institutional investors in ArriVent BioPharma, Inc. (NASDAQ:AVBP) have had a wonderful week after share price increased 15% - Simply Wall St
BNP Paribas Financial Markets Takes $83,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) institutional investors have had a good week as stock gains 19% - Yahoo Finance
Oppenheimer starts ArriVent BioPharma at outperform - MSN
ArriVent BioPharma (NASDAQ:AVBP) & Indivior (NASDAQ:INDV) Head to Head Survey - Defense World
ArriVent BioPharma shares upgraded with Outperform rating - Investing.com
ArriVent BioPharma shares upgraded with Outperform rating By Investing.com - Investing.com Nigeria
ArriVent BioPharma (NASDAQ:AVBP) Earns Outperform Rating from Analysts at Oppenheimer - Defense World
ArriVent BioPharma shares upgraded with Outperform rating - Investing.com India
ArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at Oppenheimer - MarketBeat
ArriVent BioPharma shares upgraded with Outperform rating By Investing.com - Investing.com UK
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down to $19.65 - MarketBeat
ArriVent BioPharma, Inc.'s Lock-Up Period Set To Expire on July 24th (NASDAQ:AVBP) - MarketBeat
1.26%
1.94%
大文字化:
|
ボリューム (24 時間):